Latest NewsSep 25, 2025HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) All Filter By: Year20252024202320222021202020192018201720162015Oct 9, 2023HiFiBiO Therapeutics Receives Approval from Chinese NMPA for IND Application for HFB200301, an Innovative Anti-Tumor Monoclonal AntibodyAug 28, 2023Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023Jun 28, 2023Robert Andtbacka, MD, CM joins HiFiBiO Therapeutics as Chief Medical OfficerJun 23, 2023HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid TumorsBiotech2050 | Podcast | Jun 14, 2023HiFiBiO Therapeutics CEO Liang Schweizer Shares Her Professional Journey and the Company’s Pioneering DIS® Approach on the Biotech2050 Podcast< 1 2 3 4 5 6 … 18 >
